HRP20171209T1 - Farmaceutski pripravak za liječenje upalnih bolesti posredovanih putem mcp-1 - Google Patents
Farmaceutski pripravak za liječenje upalnih bolesti posredovanih putem mcp-1 Download PDFInfo
- Publication number
- HRP20171209T1 HRP20171209T1 HRP20171209TT HRP20171209T HRP20171209T1 HR P20171209 T1 HRP20171209 T1 HR P20171209T1 HR P20171209T T HRP20171209T T HR P20171209TT HR P20171209 T HRP20171209 T HR P20171209T HR P20171209 T1 HRP20171209 T1 HR P20171209T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- group
- composition according
- amlodipine
- diltiazem
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (8)
1. Farmaceutski sastav, naznačen time, da obuhvaća sljedeće:
(a) spoj 2-((1-benzil-3-indazolil)metoksi)-2-metil-propionske kiseline, koji ima sljedeću strukturnu formulu:
[image]
(b) najmanje jedno od (i) sredstvo za smanjenje tlaka odabrano od ACE-inhibitora, od sredstava ARB i CCB, i/ili (ii) sredstvo za sniženje kolesterola odabrano od derivata statina, ili njihova bilo koja farmaceutski prihvatljiva sol i njihov takav ester, i
(c) najmanje jedan farmaceutski prikladan nosač;
gdje
navedeni ACE-inhibitor je odabran iz skupine koju čine alacepril, altiopril-kalcij, benzoilkaptopril, kaptopril, kaptopril-cistein, kaptopril-glutation, ceronapril, konverstatin, enalapril, enalaprilat, epikaptopril, fosinopril, fosinopril-natrij, fosinoprilat, hemorfin-4, indolapril, indolaprilat, lizinopril, moveltipril, pentopril, perindopril, perindoprilat, kvinapril, kvinapril-hidroklorid, kvinaprilat, ramipril, ramiprilat, spirapril, spirapril-hidroklorid, spiraprilat, trandolapril, trandolaprilat, zabicipril, zabiciprilat, zofenopril, zofenoprilat,
dok je navedeni ARB odabran iz skupine koju čine kandesartan, cileksetil, irbesartan, losartan, olmesartan, telmisartan, valsartan i pratosartan,
a navedeni CCB je odabran iz skupine koju čine amlodipin, aranidipin, barnidipin, benidipin, kilnidipin, efonidipin, elgodipin, felodipin, izradipin, lacidipin, lerkanidipin, manidipin, nikardipin, nifedipin, nilvadipin, nimodipin, nisoldipin, nitrendipin, diltiazem, klentiazem, bepridil, benciklan, etafenon, flunarizin, lidoflazin, lomerizin, mibefradil, fendilin, prenilamin, semotiadil, terodilin, galopamil i verapamil,
te je derivat statina odabran iz skupine koju čine lovastatin, mevastatin, pravastatin i simvastatin.
2. Farmaceutski sastav prema zahtjevu 1, naznačen time, da je navedeni ACE-inhibitor odabran iz skupine koju čine kaptopril, enalapril, lizinopril, ramipril i perindopril.
3. Farmaceutski sastav prema zahtjevu 1, naznačen time, da je navedeni ARB odabran iz skupine koju čine kandesartan, irbesartan, losartan i valsartan.
4. Farmaceutski sastav prema zahtjevu 1, naznačen time, da je navedeni CCB odabran iz skupine koju čine amlodipin, barnidipin, felodipin, izradipin, lacidipin, lerkanidipin, manidipin, nikardipin, nifedipin, nimodipin,
nisoldipin, nitrendipin, diltiazem, galopamil i verapamil.
5. Farmaceutski sastav prema zahtjevu 1, naznačen time, da je navedeni CCB odabran iz skupine koju čine amlodipin, verapamil i diltiazem.
6. Farmaceutski sastav prema zahtjevu 1, naznačen time, da je navedeni derivat statina odabran iz skupine koju čine lovastatin, pravastatin i simvastatin.
7. Farmaceutski sastav prema bilo kojem od prethodnih zahtjeva,
naznačen time, da navedeni farmaceutski sastav obuhvaća od 300 do 1200 mg bindarita, i jednu količinu od najmanje jednog spoja odabranog iz skupine koju čine ramipril, losartan, irbesartan, amlodipin, verapamil, diltiazem i simvastatin, prema prikazanim vrijednostima u sljedećoj tablici A1:
TABLICA A1
[image]
8. Farmaceutski sastav prema zahtjevu 7, naznačen time, da navedeni farmaceutski sastav obuhvaća maseni omjer između količine bindarita i količine od navedenog najmanje jednog spoja, kako slijedi prema prikazanim vrijednostima u tablici A2:
TABLICA A2
[image]
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09425368 | 2009-09-23 | ||
| PCT/EP2010/062979 WO2011036047A1 (en) | 2009-09-23 | 2010-09-03 | Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases |
| EP10747897.6A EP2480224B1 (en) | 2009-09-23 | 2010-09-03 | Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171209T1 true HRP20171209T1 (hr) | 2017-10-20 |
Family
ID=41722750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171209TT HRP20171209T1 (hr) | 2009-09-23 | 2010-09-03 | Farmaceutski pripravak za liječenje upalnih bolesti posredovanih putem mcp-1 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9492542B2 (hr) |
| EP (1) | EP2480224B1 (hr) |
| JP (2) | JP2013505278A (hr) |
| KR (1) | KR101774402B1 (hr) |
| CN (1) | CN102573827B (hr) |
| AR (1) | AR078307A1 (hr) |
| AU (1) | AU2010297405B2 (hr) |
| BR (1) | BR112012006149A2 (hr) |
| CA (1) | CA2760180C (hr) |
| CY (1) | CY1119125T1 (hr) |
| DK (1) | DK2480224T3 (hr) |
| EA (1) | EA021485B1 (hr) |
| ES (1) | ES2637024T3 (hr) |
| GE (1) | GEP20146067B (hr) |
| HR (1) | HRP20171209T1 (hr) |
| HU (1) | HUE033102T2 (hr) |
| IL (1) | IL218001A (hr) |
| LT (1) | LT2480224T (hr) |
| MX (1) | MX347957B (hr) |
| PL (1) | PL2480224T3 (hr) |
| PT (1) | PT2480224T (hr) |
| SG (2) | SG178414A1 (hr) |
| SI (1) | SI2480224T1 (hr) |
| SM (1) | SMT201700330T1 (hr) |
| UA (1) | UA108742C2 (hr) |
| WO (1) | WO2011036047A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5509100B2 (ja) | 2008-03-07 | 2014-06-04 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ | 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体及びそのＭＣＰ−１，ＣＸ３ＣＲ１及びｐ４０の発現に基づく疾病の治療への使用 |
| AU2009221063B2 (en) | 2008-03-07 | 2013-03-21 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, and CX3CR1 |
| US8999292B2 (en) | 2012-05-01 | 2015-04-07 | Translatum Medicus Inc. | Methods for treating and diagnosing blinding eye diseases |
| US11221321B2 (en) * | 2019-05-29 | 2022-01-11 | Imam Abdulrahman Bin Faisal University | Liquid chromatographic method for the simultaneous analysis of antihypertensive and antilipidemic agents and interactions thereof |
| EP3990433A4 (en) | 2019-06-25 | 2023-07-26 | Translatum Medicus Inc. | METHODS FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES |
| JP2023082437A (ja) * | 2021-12-02 | 2023-06-14 | 学校法人東京薬科大学 | Ｃｃｌ８による免疫細胞の動員が関与する炎症を抑制するための組成物 |
| CN116688135B (zh) * | 2023-07-28 | 2024-10-29 | 四川大学华西医院 | 一种骨关节炎药物治疗组合物及其制备方法和应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK356085A (da) | 1984-08-06 | 1986-02-07 | Upjohn Co | Reninhaemmende peptid eller et farmaceutisk acceptabelt syreadditionssalt deraf |
| MY103189A (en) | 1986-10-31 | 1993-05-29 | Pfizer | Nor-statine and nor-cyclostatine polypeptides |
| US4927807A (en) | 1987-10-06 | 1990-05-22 | Abbott Laboratories | Glaucoma treatment |
| IT1230441B (it) | 1989-02-07 | 1991-10-23 | Acraf | Eteri della serie dell'indazolo |
| CA2023099A1 (en) | 1989-09-04 | 1991-03-05 | Quirico Branca | Amino acid derivatives |
| US5209933A (en) | 1990-01-10 | 1993-05-11 | Syntex (U.S.A.) Inc. | Long acting calcium channel blocker composition |
| IE68045B1 (en) | 1990-05-11 | 1996-05-15 | Abbott Lab | Renin inhibitors |
| TW198712B (hr) | 1991-04-17 | 1993-01-21 | Hoffmann La Roche | |
| IT1253703B (it) * | 1991-04-22 | 1995-08-23 | Angelini Francesco Ist Ricerca | Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie |
| MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| US5994348A (en) * | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
| IT1276031B1 (it) | 1995-10-31 | 1997-10-24 | Angelini Ricerche Spa | Composizione farmaceutica per il trattamento delle malattie autoimmuni |
| SE9600120D0 (sv) | 1996-01-15 | 1996-01-15 | Astra Ab | Novel medical use |
| IT1293795B1 (it) * | 1997-07-28 | 1999-03-10 | Angelini Ricerche Spa | Farmaco attivo nel ridurre la produzione di proteina mcp-1 |
| US6268377B1 (en) | 1998-09-28 | 2001-07-31 | Merck & Co., Inc. | Method for treating androgen-related conditions |
| GB0111077D0 (en) | 2001-05-04 | 2001-06-27 | Biochemie Gmbh | Organic compounds |
| US20030073705A1 (en) | 2001-05-14 | 2003-04-17 | Shahnaz Shahinfar | Method of treatment |
| US20030060502A1 (en) | 2001-09-19 | 2003-03-27 | Francois Mach | Treatment of diabetes with statins (HMG-COa reductase inhibitors) |
| US7183285B2 (en) | 2004-04-29 | 2007-02-27 | Pharmix Corp. | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
| US20070060549A1 (en) | 2004-08-10 | 2007-03-15 | Friesen Albert D | Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
| US20060046996A1 (en) | 2004-08-31 | 2006-03-02 | Kowa Co., Ltd. | Method for treating hyperlipidemia |
| WO2006046528A1 (ja) * | 2004-10-29 | 2006-05-04 | Kowa Co., Ltd. | 糸球体疾患治療剤 |
| EP2526937A1 (en) | 2006-02-07 | 2012-11-28 | Mochida Pharmaceutical Co., Ltd. | Composition for prevention of recurrence of stroke |
| WO2008084504A2 (en) | 2007-01-12 | 2008-07-17 | Rubicon Research Private Limited | Pharmaceutical compositions of angiotensin ii receptor blockers |
| AU2008220785B2 (en) * | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
| JP5509100B2 (ja) | 2008-03-07 | 2014-06-04 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ | 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体及びそのＭＣＰ−１，ＣＸ３ＣＲ１及びｐ４０の発現に基づく疾病の治療への使用 |
| EA019711B1 (ru) | 2008-03-07 | 2014-05-30 | Ацьенде Кимике Рьюните Анджелини Франческо A.K.P.A.Ф. С.П.А. | ПРОИЗВОДНЫЕ 1-БЕНЗИЛ-3-ГИДРОКСИМЕТИЛИНДАЗОЛА, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, ОБУСЛОВЛЕННЫХ ЭКСПРЕССИЕЙ МСР-1, СХ3CR1 ИЛИ р40 |
| AU2009221063B2 (en) | 2008-03-07 | 2013-03-21 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, and CX3CR1 |
-
2010
- 2010-03-09 UA UAA201203482A patent/UA108742C2/uk unknown
- 2010-09-03 BR BR112012006149A patent/BR112012006149A2/pt not_active Application Discontinuation
- 2010-09-03 PT PT107478976T patent/PT2480224T/pt unknown
- 2010-09-03 WO PCT/EP2010/062979 patent/WO2011036047A1/en not_active Ceased
- 2010-09-03 SM SM20170330T patent/SMT201700330T1/it unknown
- 2010-09-03 MX MX2012003485A patent/MX347957B/es active IP Right Grant
- 2010-09-03 JP JP2012530204A patent/JP2013505278A/ja active Pending
- 2010-09-03 EA EA201270449A patent/EA021485B1/ru not_active IP Right Cessation
- 2010-09-03 SI SI201031512T patent/SI2480224T1/sl unknown
- 2010-09-03 PL PL10747897T patent/PL2480224T3/pl unknown
- 2010-09-03 ES ES10747897.6T patent/ES2637024T3/es active Active
- 2010-09-03 KR KR1020127007411A patent/KR101774402B1/ko not_active Expired - Fee Related
- 2010-09-03 DK DK10747897.6T patent/DK2480224T3/en active
- 2010-09-03 CN CN201080042390.9A patent/CN102573827B/zh not_active Expired - Fee Related
- 2010-09-03 AU AU2010297405A patent/AU2010297405B2/en not_active Ceased
- 2010-09-03 HR HRP20171209TT patent/HRP20171209T1/hr unknown
- 2010-09-03 EP EP10747897.6A patent/EP2480224B1/en active Active
- 2010-09-03 SG SG2012010302A patent/SG178414A1/en unknown
- 2010-09-03 LT LTEP10747897.6T patent/LT2480224T/lt unknown
- 2010-09-03 CA CA2760180A patent/CA2760180C/en not_active Expired - Fee Related
- 2010-09-03 GE GEAP201012675A patent/GEP20146067B/en unknown
- 2010-09-03 HU HUE10747897A patent/HUE033102T2/en unknown
- 2010-09-03 US US13/497,175 patent/US9492542B2/en not_active Expired - Fee Related
- 2010-09-03 SG SG10201405408YA patent/SG10201405408YA/en unknown
- 2010-09-22 AR ARP100103447A patent/AR078307A1/es unknown
-
2012
- 2012-02-09 IL IL218001A patent/IL218001A/en not_active IP Right Cessation
-
2015
- 2015-07-31 JP JP2015152596A patent/JP6122470B2/ja active Active
-
2017
- 2017-07-28 CY CY20171100808T patent/CY1119125T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171209T1 (hr) | Farmaceutski pripravak za liječenje upalnih bolesti posredovanih putem mcp-1 | |
| RU2014111474A (ru) | Способы лечения сердечно-сосудистых нарушений | |
| CA2613417A1 (en) | Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker | |
| ZA201102029B (en) | Pharmaceutical composition of a potent hcv inhibitor for oral administration | |
| NZ596395A (en) | Stable solid benzimidazole derivative preparation having optimized dissolution property | |
| JP2003508426A5 (hr) | ||
| SG10201503828QA (en) | N-Hydroxylsulfonamide Derivatives As New Physiologically Useful Nitroxyl Donors | |
| IL222365A (en) | 2,2 '- ({[3-Butyl-3-Ethyl-7- (Methyloxy) -1,1-Dioxide-5-Phenyl-5,4,3,2-Tetra Hydro-1, 4-Benzothiazepine-8 Methyl (imino) acetic acid | |
| IL215094A (en) | Methyl [1– {2– [5– (10– {2– [1– {2– [Methoxycarbonyl) Amino] –3 – Methylbutanoyl} pyrrolidin-2-yl] - h1– Amidazole-5-Ill} –6– Phenylindolo [2,1- c] [3,1] benzoxazine-3-yl) - h 1-amidazole-2-yl] pyrrolidin-1-yl} -3-methyl-1-oxobutan-2-yl] carbamate and preparations Hcv delay pharmacy containing it | |
| EP2291388A4 (en) | METHOD FOR PURIFYING ANTIBODIES | |
| DE502007001453D1 (de) | 4,5-diphenyl-pyrimidinyl substituierte carbonsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| IL197093A0 (en) | Pharmaceutical composition comprising candesartan cilexetil | |
| BRPI0905680A2 (pt) | "composição farmacêutica de uma composição farmacêutica" | |
| GB2454620B (en) | Solid dosage form of olmesartan medoxomil and amlodipine | |
| EP2426496A4 (en) | USE OF MEGALIN IN THE HARN AS A MARKER FOR THE DETECTION OF RENAL DISEASES | |
| EP2349250A4 (en) | FATTY ACIDS FOR USE AS MEDICAMENT | |
| SMT201400011B (it) | Composizioni farmaceutiche solide a dosaggio fissocomprendenti irbesartan e amlodipina, loro preparazione e loro applicazione terapeutiche | |
| FR2912056B1 (fr) | Composition a liberation prolongee de levetiracetam et procede de preparation | |
| EP2657272A4 (en) | CLEANING METHOD FOR A CARBOXYL-CONTAINING POLYOXYETHYLENE DERIVATIVE | |
| EP2241566A4 (en) | METHOD FOR SEPARATING AND PURIFYING EPOTHILONES | |
| JP2022511588A5 (hr) | ||
| WO2008129077A3 (en) | Crystalline 1-(cyclohexyloxycarbonyloxy) ethyl 1-((2'-cyanobiphenyl-4-yl)methyl)-2-ethoxy-1h-benzo[d]imidazole-7-carboxylate and a process for its preparation | |
| DE602007013243D1 (de) | Substituierte sulfoximine als tie2-inhibitoren und salze davon, pharmazeutische zusammensetzungen, die diese enthalten, verfahren zu ihrer herstellung und ihre anwendungen | |
| EP2441756A4 (en) | PROCESS FOR CLEANING A PYRAZOLINONE DERIVATIVE | |
| FR2903875B1 (fr) | Table a langer anti chute de securite |